Danhong inhibits oxidized low-density lipoprotein-induced immune maturation of dentritic cells via a peroxisome proliferator activated receptor γ-mediated pathway.
Danhong injection (DHI), a Chinese Materia Medica standardized product extracted from Radix Salviae miltiorrhizae and Flos Carthami tinctorii, is effective in the treatment of atherosclerosis (AS)-related diseases. It is widely recognized that AS is a complex inflammatory disease of the arterial wall and the dendritic cells (DCs) is a major player in the pathogenesis of AS via mediating atherosclerotic antigen presenting and T lymphocytes. Here, we determined the effect and possible mechanism of DHI on oxidized low-density lipoprotein (ox-LDL)-induced maturation and immune function of DCs. Human monocyte-derived DCs were incubated with DHI or ciglitazone and were subsequently stimulated with ox-LDL to induce maturation. Similar to ciglitazone, a peroxisome proliferator activated receptor (PPAR) γ agonist, DHI, could significantly reduce ox-LDL-induced expressions of mature markers, enhance the endocytotic function, and inhibit secretions of cytokine on DCs. These effects of DHI could be partly reversed by silencing the PPARγ. In conclusion, DHI could inhibit ox-LDL-induced maturation of DCs partly through activating a PPARγ-mediated signaling pathway.
Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, PR China.
Hongying
H
Liu
Shijun
S
Wang
Aijun
A
Sun
Dong
D
Huang
Wei
W
Wang
Chunyu
C
Zhang
Dazhuo
D
Shi
Keji
K
Chen
Yunzeng
Y
Zou
Junbo
J
Ge
D050197:Atherosclerosis / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016207:Cytokines / Q000276:immunology / Q000378:metabolism; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects* / Q000276:immunology*; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D004705:Endocytosis / Q000187:drug effects / Q000276:immunology; D006801:Humans; D008077:Lipoproteins, LDL / Q000276:immunology* / Q000494:pharmacology; D009000:Monocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists / Q000276:immunology / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D045162:Thiazolidinediones / Q000494:pharmacology
D016207:Cytokines; D004365:Drugs, Chinese Herbal; D008077:Lipoproteins, LDL; D047495:PPAR gamma; D045162:Thiazolidinediones; C540581:danhong; C099252:oxidized low density lipoprotein; C039671:ciglitazone